Webcast

Out of the Shadows: Starting the Conversation About Bowel Urgency in Patients with Crohn’s Disease

Launch Date
02/01/2024 at 5:00 am EST
Credit Amount
1.5
Credit Expires
02/01/2025

Faculty

Marla Dubinsky, MD
Moderator
Professor of Pediatrics and Medicine 
Co-Director, Susan and Leonard Feinstein IBD Clinical Center 
Director, Marie and Barry Lipman IBD Preconception and Pregnancy Clinic 
Icahn School of Medicine, Mount Sinai New York 
Chief, Division of Pediatric GI and Nutrition 
Mount Sinai Kravis Children’s Hospital
New York, NY
Tauseef Ali, MD, FACP, FACG, AGAF
Medical Director 
SSM Health Crohn's and Colitis Center 
Medical Executive Director 
SSM Health Digestive Care 
Clinical Associate Professor 
University of Oklahoma Health Sciences Center 
Oklahoma City, OK
Millie D. Long, MD, MPH
Professor of Medicine
Vice-Chief for Education
Director, Gastroenterology and Hepatology Fellowship Program
Division of Gastroenterology and Hepatology
University of North Carolina 
Chapel Hill, NC 
Millie D. Long, MD, MPH

Millie D. Long, MD, MPH, is board certified in internal medicine, preventive medicine, and gastroenterology. Dr. Long received her medical degree from University of Virginia in 2002. She then completed residency in internal medicine and a chief residency at University of Alabama at Birmingham. She completed fellowships in gastroenterology and hepatology, preventive medicine, and inflammatory bowel disease, all at University of North Carolina. She is currently Professor of Medicine in the Department of Medicine and Director of the Gastroenterology and Hepatology Fellowship Program at University of North Carolina at Chapel Hill.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) Center. Her research interests include prevention of complications of IBD, women’s health, and clinical epidemiology. Dr. Long has contributed to over 200 peer-reviewed publications, book chapters, and review articles and to the medical literature. She is the current co-Editor in Chief of the American Journal of Gastroenterology. She also serves as an invited reviewer for journals such as Inflammatory Bowel Diseases and Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology, where she serves on the Board of Trustees. She is also a fellow of the American Gastroenterological Association and the Crohn’s and Colitis Foundation, where she co-chairs the Clinical Research Alliance.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

Studies demonstrate that approximately 65%-82% of patients with Crohn’s disease (CD) report at least some degree of bowel urgency, but this symptom is largely underrecognized by gastroenterologists and health care professionals (HCPs) caring for patients with inflammatory bowel disease (IBD). There is a lack of awareness and appreciation of the impact of bowel urgency in patients with CD as it is most commonly associated with ulcerative colitis. Bowel urgency in patients with CD results in emotional and social stress, leading to stigma, feelings of isolation, and impacting all aspects of daily life for patients. Bowel urgency is not widely incorporated into clinical assessment indices or clinical trial endpoints for CD, despite being a pivotal symptom influencing patient health-related QoL (HRQoL) and a potential indicator of uncontrolled intestinal inflammation.

In this CMEO Outfitters recorded symposium, expert faculty discuss recognizing the frequency of bowel urgency in patients with CD and the impact on patient QoL, incorporating assessments for bowel urgency through symptom evaluation, and engaging patients in open communication about their bowel urgency as part of shared decision-making in order to improve clinical outcomes, and the faculty also review real-world patient cases.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Recognize the frequency of bowel urgency in patients with CD and the impact on patient quality of life
  • Incorporate assessments for bowel urgency as part of thorough symptom evaluation for patients with CD
  • Engage patients in open communication about their bowel urgency as part of shared decision-making in order to improve clinical outcomes

Financial Support

This activity is supported by an educational grant from Lilly.

Target Audience

Primary:  Gastroenterologists, physician associates (PAs), and nurse practitioners (NPs)
Secondary:  Nurses and pharmacists

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 1.5

This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME) 1.5

CME Outfitters, LLC, designates this Enduring Material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.5

This activity is designated for 1.50 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.

Pharmacists (ACPE) 1.5

This application-based activity is approved for 1.50 contact hours (0.15 CEUs) of continuing pharmacy credit (JA0007185-0000-24-006-H01-P).

PAs (AAPA) 1.50

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid until 02/01/2025. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 1.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

Dr. Dubinsky reports the following financial relationships:

Advisory Board and Consultant: AbbVie Inc.; Abivax; AstraZeneca; Bristol Myers Squibb Company; Janssen Biotech, Inc.; Lilly; Merck & Co., Inc; Pfizer Inc.; Prometheus Biosciences; Prometheus Laboratories; and Takeda Pharmaceuticals U.S.A., Inc.

Dr. Ali reports the following financial relationships:

Advisory Board: AbbVie Inc. and Janssen Pharmaceuticals, Inc.

Consultant: AbbVie Inc.; Boehringer Ingelheim; E.R. Squibb & Sons, L.L.C.; and Fresenius Kabi USA

Research Support: AbbVie Inc.; Arena Pharmaceuticals; AstraZeneca; and Celgene Corporation

Speakers Bureau: AbbVie Inc.; E.R. Squibb & Sons, L.L.C.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Dr. Long reports the following financial relationships:

Consultant: AbbVie Inc.; Bristol Myers Squibb Company; Intercept Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer Inc.; Prometheus Biosciences, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Target RWE

Research Support: Lilly; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

The following individuals have no financial relationships to disclose: 

Rebecca Vargas-Jackson, MD  (Peer Reviewer)
Shirley Michelle Franks, MSN, APRN, FNP-BC (Peer Reviewer)
Susan Perry (Planning Committee)
Kasey Brandt, PharmD (Planning Committee)
Susan H. Yarbrough, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

MMV-136-012524-11

Out of the Shadows: Starting the Conversation About Bowel Urgency in Patients with Crohn’s Disease
Event Date: 02/01/2024 at 5:00 am EST
Begin

Related Activities

Gastroenterology
11/04/2024

How Low Can You Go? Targeting of Deep Remission in the Management of Crohn’s Disease

1.5
Begin Learn More
Gastroenterology
10/18/2024

Optimizing Ulcerative Colitis Management: Navigating Challenges and Enhancing Outcomes in Managed Care

1.5
Begin Learn More
Diversity & Inclusion
08/29/2024

Take Action: Optimizing Equity in Gastroenterology Care

1
Begin Learn More